RVNC - Enrollment underway in Revance Therapeutics' late-stage DaxibotulinumtoxinA study

Revance Therapeutics (RVNC) announces that collaborator Shanghai Fosun Pharmaceutical has initiated Phase 3 trials of DaxibotulinumtoxinA for Injection in China, for the treatment of glabellar lines and cervical dystonia.Both trials enrolled and dosed their first patients in April.Revance entered into a license agreement with Fosun Pharma Industrial in 2018, whereby latter received exclusive rights to develop and commercialize Revance’s long-acting neuromodulator, DaxibotulinumtoxinA for Injection, in mainland China, Hong Kong and Macau.

For further details see:

Enrollment underway in Revance Therapeutics' late-stage DaxibotulinumtoxinA study